Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)

NCT04196101 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

NCT NCT04196101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04196101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2020
Completion date
January 4, 2022
Enrollment
82 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus